Edoxaban Tosylate Monohydrate is the salt form of edoxaban, a direct oral factor Xa inhibitor that blocks the conversion of prothrombin to thrombin in the coagulation cascade. It is widely prescribed for stroke prevention in non-valvular atrial fibrillation and for treating venous thromboembolism. Simson Pharma supplies the reference standard and its pharmacopoeial impurities to support the rapidly growing generic DOAC segment.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Edoxaban Tosylate Monohydrate Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.